Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

This study has been terminated.
(This study was terminated for futility)
Information provided by (Responsible Party):
BioCryst Pharmaceuticals Identifier:
First received: August 12, 2009
Last updated: July 17, 2014
Last verified: July 2014

A Phase 3, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and adolescents who are hospitalized due to serious influenza.

Condition Intervention Phase
Sore Throat
Nasal Congestion
Seasonal Influenza
Drug: Peramivir 600mg Adults, Peramivir 10mg/kg Adolescents
Drug: Placebo Peramivir
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Serious Influenza

Resource links provided by NLM:

Further study details as provided by BioCryst Pharmaceuticals:

Primary Outcome Measures:
  • Measurement of vital signs and oxygen saturation will be summarized by visit, changes from baseline. [ Time Frame: Thru Day 10 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in quantitative viral load over time and change from baseline measured from nasopharyngeal swab samples, as determined by quantitative virus culture (and retrospectively by RT-PCR, if available) [ Time Frame: Thru Day 10 ] [ Designated as safety issue: No ]

Enrollment: 406
Study Start Date: November 2009
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Peramivir 600mg Adults, Peramivir 10mg/kg Adolescents
  • Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
  • Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
Drug: Peramivir 600mg Adults, Peramivir 10mg/kg Adolescents
  • Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
  • Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
Placebo Comparator: Placebo Peramivir
Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
Drug: Placebo Peramivir
Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.


Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥12 years of age, male or female.
  • Able to provide informed consent, or for whom consent may be provided by guardian, unless informed consent provided by a guardian or a legally authorized representative is not consistent with applicable local or ethical concerns, procedures, directives and/or guidelines.
  • Subject must have at least one of the following clinical presentations at Screening:

    1. Oral temperature ≥ 38.0 °C (≥100.4 °F), ≥38.6°C (≥101.4 °F) tympanic or rectal OR
    2. Oxygen saturation <92%, OR
    3. Two out of the following three vital signs:

Respiration rate >24/minute, Heart rate >100/minute, Systolic BP <90 mmHg

  • Presence of at least one respiratory symptom (cough, sore throat, or nasal congestion) of any severity (mild, moderate, or severe).
  • Presence of at least one constitutional symptom (headache, myalgia, feverishness, or fatigue) of any severity (mild, moderate, or severe).
  • Onset of illness no more than 72 hours before presentation. Note: Time of onset of illness is defined as the earlier of either (1) the time when the temperature was first measured as elevated, OR (2) the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.
  • Either:

Severity of illness that, in the Investigator's judgment, justifies hospitalization of the subject for supportive care.


Presence of one or more of the following factors:

Age ≥60 years. Presence of chronic obstructive pulmonary disease (COPD) or other chronic lung disease requiring daily pharmacotherapy.

Current history of congestive heart failure or angina. Presence of diabetes mellitus, clinically stable or unstable. Transcutaneous oxygen saturation <94% without supplemental oxygen for at least 5 minutes, or a medically significant decrease in oxygen saturation from an established baseline value (an investigative site at altitude >2000 ft above sea level will utilize different criteria for oxygen saturation).

History of chronic renal impairment not requiring peritoneal dialysis. Serum creatinine > 2.0 mg/dL or > 200 μmol/L.

  • Diagnosis of Influenza by satisfying one of the following:

    1. Clinical Influenza with Positive Diagnostic Test. Subjects who have a positive rapid antigen test (RAT) for influenza A and/or influenza B (using a Sponsor-approved test kit), or positive test (using other methodology) for influenza A and/or B virus antigen or RNA performed in a clinical laboratory at the screening/enrollment evaluation are eligible for enrollment.


    2. Clinical Influenza with Negative Rapid Antigen Test (RAT). Subjects with a negative RAT test may be enrolled once the site has been approved by the Sponsor to enroll such subjects, based on documentation of an outbreak of influenza in the community. An influenza outbreak may be documented in the catchment area of the hospital via one of the following methods: 1) local confirmation of influenza A or B infection in the current influenza season by a) the institution's local laboratory, or b) the local public health system, or c) the national public health system, or d) a laboratory of a recognized multinational influenza surveillance scheme such as the European Influenza Surveillance Network (EISN); 2) prior enrollment of a RAT positive subject into this study at the same institution in the current influenza season.

      Exclusion Criteria:

  • Subjects who have been hospitalized for greater than 24 hours (not including time spent in the Emergency Department).
  • Treatment with any dose(s) of rimantadine, amantadine, ribavirin, zanamivir, or oseltamivir in the previous 7 days.
  • Blood platelet count of < 20 x 109/L at the time of the screening evaluation.
  • Serum bilirubin > 6 mg/dL or > 105 μmol/L at time of screening evaluation.
  • Serum ALT or AST > 5 times the upper limit of normal at time of screening evaluation.
  • Congestive heart failure of NYHA Class III or Class IV functional status.
  • Serum creatinine > 5.0 mg/dL or > 500 μmol/L at time of screening evaluation.
  • Subjects who require peritoneal dialysis.
  • Altered neurologic status as defined by a Glasgow Coma Score of ≤ 9, unless medically induced.
  • Females who are pregnant (positive urine or serum pregnancy test at screening evaluation) or breastfeeding.
  • Actively undergoing systemic chemotherapy or radiotherapy treatment for a malignancy. Subjects who have completed treatment 30 days prior to enrollment are not excluded. Hormone treatment for cancer is also not excluded.
  • Prior hematopoietic stem cell transplantation or solid organ transplant during the previous 4 months.
  • HIV infection with a known CD4 count < 200 cells/mm3 unless on a stable highly active antiretroviral therapy (HAART) for at least 6 months.
  • Presence of a pre-existing chronic infection that is undergoing or requiring medical therapy (eg, tuberculosis). Subjects with chronic osteomyelitis or Hepatitis B or C not requiring treatment are not excluded.
  • Presence of any pre-existing illness that, in the opinion of the investigator, would place the subject at an unreasonably increased risk through participation in this study.
  • Previous treatment with intravenous or intramuscular peramivir.
  • Participation as a subject in any study of an experimental treatment for any condition within the 30 days prior to the time of the screening evaluation.
  • Subjects diagnosed with Cystic Fibrosis.
  • Subjects with confirmed clinical evidence of acute non-influenzal infection at the time of screening evaluation.
  • Subjects who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00958776

  Hide Study Locations
United States, California
La Mesa, California, United States
Long Beach, California, United States
Modesto, California, United States
Oceanside, California, United States
Orange, California, United States
Sacramento, California, United States
San Diego, California, United States
United States, Colorado
Denver, Colorado, United States
Wheat Ridge, Colorado, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Ft. Lauderdale, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
West Palm Beach, Florida, United States
United States, Georgia
Columbus, Georgia, United States
Decatur, Georgia, United States
Savannah, Georgia, United States
United States, Hawaii
Honolulu, Hawaii, United States
United States, Illinois
Moline, Illinois, United States
Springfield, Illinois, United States
United States, Indiana
South Bend, Indiana, United States
United States, Kentucky
Hazard, Kentucky, United States
United States, Louisiana
Natchitoches, Louisiana, United States
New Orleans, Louisiana, United States
United States, Maryland
Annapolis, Maryland, United States
Baltimore, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Detroit, Michigan, United States
Royal Oak, Michigan, United States
Troy, Michigan, United States
United States, Missouri
St. Louis, Missouri, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Jersey
New Brunswick, New Jersey, United States
United States, New York
Bronx, New York, United States
Manhasset, New York, United States
New York, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
United States, Ohio
Columbus, Ohio, United States
Dayton, Ohio, United States
Kettering, Ohio, United States
Lima, Ohio, United States
Toledo, Ohio, United States
United States, Pennsylvania
Allentown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
United States, Rhode Island
East Providence, Rhode Island, United States
United States, South Carolina
Charleston, South Carolina, United States
United States, South Dakota
Sioux Falls, South Dakota, United States
United States, Texas
San Antonio, Texas, United States
United States, Virginia
Charlottesville, Virginia, United States
Roanoke, Virginia, United States
Salem, Virginia, United States
Buenos Aires, Argentina
Caba, Argentina
Cordoba, Argentina
Mendoza, Argentina
Merlo, Argentina
Rosario, Argentina
Santa Fe, Argentina
Vicente Lopez, Argentina
Bruxelles, Belgium
Liege, Belgium
Mons, Belgium
Bosnia and Herzegovina
Sarajevo, Bosnia and Herzegovina
Tuzla, Bosnia and Herzegovina
Belo Horizonte, MG, Brazil
Curitiba, PR, Brazil
Passo Fundo, RS, Brazil
Porto Alegre, RS, Brazil
Campinas, SP, Brazil
Santo Andre, SP, Brazil
Santos, SP, Brazil
Sao Paulo, SP, Brazil
Plovdiv, Bulgaria
Ruse, Bulgaria
Sofia, Bulgaria
Stara Zagora, Bulgaria
Veliko Tarnovo, Bulgaria
Canada, British Columbia
Kelowna, British Columbia, Canada
Canada, Ontario
Hamilton, Ontario, Canada
Kingston, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Chicoutimi, Quebec, Canada
Sherbrooke, Quebec, Canada
Quebec, Canada
Concepcion, Chile
Santiago, Chile
Temuco, Chile
Czech Republic
Brno, Czech Republic
Hradec Kralove, Czech Republic
Praha, Czech Republic
Tabor, Czech Republic
Usti nad Labem, Czech Republic
Berlin, Germany
Erlangen, Germany
Goettingen, Germany
Koeln, Germany
Mainz, Germany
Regensburg, Germany
Debrecen, Hungary
Fehergyarmat, Hungary
Szekesfehervar, Hungary
Szentes, Hungary
Zalaegerszeg, Hungary
Hyderabad, Andhra Pradesh, India
Secunderabad, Andhra Pradesh, India
Ahmedabad, Gujarat, India
Karamsad, Gujarat, India
Surat, Gujarat, India
Vadodara, Gujarat, India
Faridabad, Haryana, India
Srinagar, Jammu & Kashmir, India
Bangalore, Karnataka, India
Mangalore, Karnataka, India
Ernakulam, Kerala, India
Thrissur, Kerala, India
Trivandrum, Kerala, India
Cherthala, Maharashtra, India
Mumbai, Maharashtra, India
Nagpur, Maharashtra, India
Nashik, Maharashtra, India
Pune, Maharashtra, India
Mohali, Punjab, India
Bikaner, Rajasthan, India
Jaipur, Rajasthan, India
Chennai, Tamil Nadu, India
Coimbatore, Tamil Nadu, India
Lucknow, Uttar Pradesh, India
Kolkata, West Bengal, India
Delhi, India
Afula, Israel
Haifa, Israel
Holon, Israel
Jerusalem, Israel
Kfar Saba, Israel
Ramat Gan, Israel
Tel Aviv, Israel
Liepaja, Latvia
Rezekne, Latvia
Valmiera, Latvia
Ventspils, Latvia
Beirut, Lebanon
Arequipa, Peru
Cuzco, Peru
Lima, Peru
Bydgoszcz, Poland
Lancut, Poland
Lodz, Poland
Mielec, Poland
Poznan, Poland
Pulawy, Poland
Russian Federation
Engels, Russian Federation
Niznhy Novgorod, Russian Federation
Novosibirsk, Russian Federation
St. Petersburg, Russian Federation
Tomsk, Russian Federation
Belgrade, Serbia
Kragujevac, Serbia
Nis, Serbia
Novi Sad, Serbia
Trnava, Slovakia
South Africa
Middelburg, Mpumalanga, South Africa
Bloemfontein, South Africa
Dundee, South Africa
Durban, South Africa
Krugersdorp, South Africa
Limpopo, South Africa
Port Elizabeth, South Africa
Pretoria, South Africa
Somerset West, South Africa
Worcester, South Africa
Chernivci, Ukraine
Donetsk, Ukraine
Kharkiv, Ukraine
Kyiv, Ukraine
Odesa, Ukraine
Poltava, Ukraine
Sumy, Ukraine
Vinnytsya, Ukraine
United Kingdom
Leicester, United Kingdom
Sponsors and Collaborators
BioCryst Pharmaceuticals
  More Information

No publications provided

Responsible Party: BioCryst Pharmaceuticals Identifier: NCT00958776     History of Changes
Other Study ID Numbers: BCX1812-301
Study First Received: August 12, 2009
Last Updated: July 17, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by BioCryst Pharmaceuticals:

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases processed this record on November 20, 2014